NCT03936829Active, not recruiting
Cyclophosphamide in the Treatment of Associated Acquired Lipodystrophy Syndrome With Type 1 Diabetes
Cyclophosphamide in the Treatment of Panniculitis Associated Acquired Lipodystrophy Syndrome With Type 1 Diabetes
Source: ClinicalTrials.gov · Last updated 17 Mar 2026
Brief summary (registry, in English)
This study evaluates the change of insulin resistance and glucose metabolism of patients with panniculitis associated acquired lipodystrophy syndrome and type 1 diabetes with the treatment of cyclophosphamide.
- Status (registry)
- Active, not recruiting
- Study type
- Interventional
- Enrollment
- 10 (estimated)
- First submitted
- 25 Apr 2019
- Start date
- 28 Apr 2019
- Primary completion date
- 31 May 2028
- Lead sponsor
- Children's Hospital of Fudan University
- Diseases
- Type 1 diabetes
- NCT number
- NCT03936829
What you commit to
- Study type: Interventional
- Planned participants: 10
- From 28 Apr 2019 to the primary completion date, 31 May 2028
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- HIV, HBV and HCV were positive.
- A the active period of infection.
- At the active stage of malignant tumors.
- Combination of other fatal diseases.
- Existence of mental and psychological diseases.
Other
- Mature and effective treatment methods are available.
Who the study is looking for
- Meet the diagnostic criteria of type 1 diabetes mellitus: clinical manifestations of typical diabetes mellitus include polyphagia, polyuria, weight loss, or diabetic ketoacidosis, confirmed by blood sugar level, islet function and autoimmune antibody.
- Meet the diagnostic criteria for panniculitis: fat biopsy suggests inflammatory infiltration.
- Meet the diagnostic criteria for acquired lipodystrophy syndrome: childhood onset, clinically no nutritional deficiency or catabolism, systemic or partial subcutaneous fat reduction, genetic testing to exclude congenital lipodystrophy syndrome; low leptin level and autoantibodies can aid in diagnosis.
Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Children's Hospital Of Fudan University Coordinator of this site? Confirm its status | Shanghai | China | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.